ES2273599B1 - Compuestos para el tratamiento de la fibrilacion auricular. - Google Patents

Compuestos para el tratamiento de la fibrilacion auricular. Download PDF

Info

Publication number
ES2273599B1
ES2273599B1 ES200502545A ES200502545A ES2273599B1 ES 2273599 B1 ES2273599 B1 ES 2273599B1 ES 200502545 A ES200502545 A ES 200502545A ES 200502545 A ES200502545 A ES 200502545A ES 2273599 B1 ES2273599 B1 ES 2273599B1
Authority
ES
Spain
Prior art keywords
receptor
antagonist
atrial fibrillation
calcium
atrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200502545A
Other languages
English (en)
Spanish (es)
Other versions
ES2273599A1 (es
Inventor
Rafael Franco Fernandez
Francisco Ciruela Alferez
Carme Lluis Biset
Christa Muller
Joan Cinca Cuscullola
Leif Hove-Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Original Assignee
Universitat de Barcelona UB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200502545A priority Critical patent/ES2273599B1/es
Application filed by Universitat de Barcelona UB filed Critical Universitat de Barcelona UB
Priority to JP2008535047A priority patent/JP2009511551A/ja
Priority to CN200680046601XA priority patent/CN101325956B/zh
Priority to DK06830873.3T priority patent/DK1949903T3/da
Priority to ES06830873T priority patent/ES2386377T3/es
Priority to PCT/ES2006/000564 priority patent/WO2007045705A2/es
Priority to RU2008118995/15A priority patent/RU2445099C2/ru
Priority to US12/090,115 priority patent/US8012973B2/en
Priority to MX2008004886A priority patent/MX2008004886A/es
Priority to CA002626020A priority patent/CA2626020A1/en
Priority to AU2006303240A priority patent/AU2006303240B2/en
Priority to AT06830873T priority patent/ATE553763T1/de
Priority to BRPI0617369-1A priority patent/BRPI0617369A2/pt
Priority to EP06830873A priority patent/EP1949903B8/en
Publication of ES2273599A1 publication Critical patent/ES2273599A1/es
Application granted granted Critical
Publication of ES2273599B1 publication Critical patent/ES2273599B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
ES200502545A 2005-10-14 2005-10-14 Compuestos para el tratamiento de la fibrilacion auricular. Expired - Fee Related ES2273599B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES200502545A ES2273599B1 (es) 2005-10-14 2005-10-14 Compuestos para el tratamiento de la fibrilacion auricular.
AU2006303240A AU2006303240B2 (en) 2005-10-14 2006-10-10 Compounds for the treatment of atrial fibrillation
DK06830873.3T DK1949903T3 (da) 2005-10-14 2006-10-10 Selektive A2A-receptor-antagonister til behandling af atrieflimmer
ES06830873T ES2386377T3 (es) 2005-10-14 2006-10-10 Antagonistas selectivos del receptor A2A para el tratamiento de la fibrilación auricular
PCT/ES2006/000564 WO2007045705A2 (es) 2005-10-14 2006-10-10 Compuestos para el tratamiento de la fibrilación auricular
RU2008118995/15A RU2445099C2 (ru) 2005-10-14 2006-10-10 Селективные антагонисты аденозинового рецептора a2a для изготовления лекарственного средства для лечения фибрилляции предсердий
US12/090,115 US8012973B2 (en) 2005-10-14 2006-10-10 Compounds for the treatment of auricular fibrillation
MX2008004886A MX2008004886A (es) 2005-10-14 2006-10-10 Compuestos para el tratamiento de la fibrilacion auricular.
JP2008535047A JP2009511551A (ja) 2005-10-14 2006-10-10 心房細動の治療のための化合物
CN200680046601XA CN101325956B (zh) 2005-10-14 2006-10-10 治疗心房颤动的化合物
AT06830873T ATE553763T1 (de) 2005-10-14 2006-10-10 Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern
BRPI0617369-1A BRPI0617369A2 (pt) 2005-10-14 2006-10-10 compostos para tratamento de fibrilaÇço auricular
EP06830873A EP1949903B8 (en) 2005-10-14 2006-10-10 Selective a2a receptor antagonists for the treatment of auricular fibrillation
CA002626020A CA2626020A1 (en) 2005-10-14 2006-10-10 Compounds for the treatment of atrial fibrillation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200502545A ES2273599B1 (es) 2005-10-14 2005-10-14 Compuestos para el tratamiento de la fibrilacion auricular.

Publications (2)

Publication Number Publication Date
ES2273599A1 ES2273599A1 (es) 2007-05-01
ES2273599B1 true ES2273599B1 (es) 2008-06-01

Family

ID=37962872

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200502545A Expired - Fee Related ES2273599B1 (es) 2005-10-14 2005-10-14 Compuestos para el tratamiento de la fibrilacion auricular.
ES06830873T Active ES2386377T3 (es) 2005-10-14 2006-10-10 Antagonistas selectivos del receptor A2A para el tratamiento de la fibrilación auricular

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06830873T Active ES2386377T3 (es) 2005-10-14 2006-10-10 Antagonistas selectivos del receptor A2A para el tratamiento de la fibrilación auricular

Country Status (13)

Country Link
US (1) US8012973B2 (enExample)
EP (1) EP1949903B8 (enExample)
JP (1) JP2009511551A (enExample)
CN (1) CN101325956B (enExample)
AT (1) ATE553763T1 (enExample)
AU (1) AU2006303240B2 (enExample)
BR (1) BRPI0617369A2 (enExample)
CA (1) CA2626020A1 (enExample)
DK (1) DK1949903T3 (enExample)
ES (2) ES2273599B1 (enExample)
MX (1) MX2008004886A (enExample)
RU (1) RU2445099C2 (enExample)
WO (1) WO2007045705A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105785053B (zh) * 2011-10-17 2018-09-21 霍夫曼-拉罗奇有限公司 风险患者和中风原因的基于肌钙蛋白和bnp的诊断
CZ2014307A3 (cs) * 2014-05-06 2016-01-13 Vysoká škola chemicko- technologická v Praze Kofein-8-hydrazony jako nová cytostatika pro léčbu onkologických onemocnění
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
CN108570054B (zh) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
CN112533923B (zh) 2018-06-04 2024-07-09 爱克思科技有限公司 作为腺苷受体拮抗剂的吡唑并嘧啶化合物
CN108864114B (zh) 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US20230218716A1 (en) * 2020-05-06 2023-07-13 Ohio State Innovation Foudation Compositions and methods for treating atrial fibrillation
KR102675647B1 (ko) * 2021-06-30 2024-06-18 단국대학교 천안캠퍼스 산학협력단 인간치아줄기세포의 상아모세포로의 분화를 위한 신규 화합물 및 이의 의학적 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998387A (en) * 1993-10-28 1999-12-07 University Of Florida Research Foundation, Inc. Method for using A1 adenosine receptor agonists
WO2001040245A1 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. N6 heterocyclic 5' modified adenosine derivatives
WO2002055524A1 (en) * 2001-01-10 2002-07-18 Vernalis Research Limited THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US599387A (en) * 1898-02-22 Cabinet
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4780464A (en) * 1986-12-08 1988-10-25 Warner-Lambert Company (1,2,4)triazolo(4,3-a)quinoxaline-4-amines
CA2094270C (en) 1990-10-18 1997-01-21 Fumio Suzuki Xanthine derivatives
GB9124968D0 (en) * 1991-11-25 1992-01-22 Ici Plc Chemical process
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
US5543415A (en) 1992-07-08 1996-08-06 Kyowa Hakko Kogyo Co., Ltd. Antidepressants
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
ATE218139T1 (de) 1994-02-23 2002-06-15 Kyowa Hakko Kogyo Kk Xanthin-derivate
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JP4195729B2 (ja) 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
EP1016407B1 (en) 1997-09-05 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating brain ischemia
US6197788B1 (en) 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
DE19930558A1 (de) 1998-07-24 2000-01-27 Marquardt Gmbh Elektrischer Schalter
EP1109801A1 (en) * 1998-09-04 2001-06-27 The Procter & Gamble Company Substituted dihydrobenzopyrans useful as antiarrhythmic agents
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
AU4431000A (en) 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
WO2001002400A1 (en) 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
JP3347691B2 (ja) * 1999-07-05 2002-11-20 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド 抗不整脈及び抗細動剤として有用な新規４−オキソ環式尿素類
BR0013673A (pt) 1999-08-31 2002-05-28 Univ Vanderbilt Antagonistas seletivos de receptores de adenosina a2b
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6194366B1 (en) 1999-11-16 2001-02-27 Esc, Inc. Post chemical-mechanical planarization (CMP) cleaning composition
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2398274C (en) 2000-02-25 2009-09-22 F. Hoffmann-La Roche Ag Adenosine receptor modulators
EP1510222A3 (en) 2000-04-26 2007-05-23 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
MXPA02011625A (es) 2000-05-26 2003-03-27 Schering Corp Antagonistas receptores de adenosina a2a.
KR100526487B1 (ko) 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
MXPA03001136A (es) 2000-08-11 2003-06-24 Eisai Co Ltd Compuesto de 2-aminopiridina y uso medico del mismo.
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
AU2002352933A1 (en) 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
ATE453647T1 (de) 2001-11-30 2010-01-15 Schering Corp Adenosin a2a rezeptor antagonisten
ES2279903T3 (es) 2001-12-18 2007-09-01 Cv Therapeutics, Inc. Antagonistas del receptor a2a de adenosina.
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
AU2002950853A0 (en) 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
JP4498140B2 (ja) 2002-08-30 2010-07-07 協和発酵キリン株式会社 行動障害治療剤
CA2500228A1 (en) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]-triazolo[1,5-c]pyrimidine derivative
NZ540493A (en) 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
WO2004085439A1 (en) * 2003-03-27 2004-10-07 Pfizer Products Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
EA200600688A1 (ru) 2003-10-03 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
EP1678160A1 (en) 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CA2547248A1 (en) 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
WO2005058883A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998387A (en) * 1993-10-28 1999-12-07 University Of Florida Research Foundation, Inc. Method for using A1 adenosine receptor agonists
WO2001040245A1 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. N6 heterocyclic 5' modified adenosine derivatives
WO2002055524A1 (en) * 2001-01-10 2002-07-18 Vernalis Research Limited THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERTOLET, B.D et al.: "Myocardial infarction related atrial fibrillation: role of endogenous adenosine". Heart, 1997, vol. 78, páginas 88-90, todo el documento. 1,2\\ X US 4772607 A (BADGER et al.) 20.09.1988, columnas 2,3. *

Also Published As

Publication number Publication date
CN101325956A (zh) 2008-12-17
JP2009511551A (ja) 2009-03-19
ATE553763T1 (de) 2012-05-15
RU2445099C2 (ru) 2012-03-20
WO2007045705A2 (es) 2007-04-26
ES2273599A1 (es) 2007-05-01
WO2007045705A3 (es) 2007-06-14
CN101325956B (zh) 2012-02-29
BRPI0617369A2 (pt) 2011-07-26
EP1949903B1 (en) 2012-04-18
MX2008004886A (es) 2009-03-02
DK1949903T3 (da) 2012-07-30
CA2626020A1 (en) 2007-04-26
AU2006303240B2 (en) 2012-07-12
ES2386377T3 (es) 2012-08-20
US8012973B2 (en) 2011-09-06
RU2008118995A (ru) 2009-11-20
EP1949903B8 (en) 2012-05-23
US20090312332A1 (en) 2009-12-17
AU2006303240A1 (en) 2007-04-26
EP1949903A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
US11246879B2 (en) Methods, agents, and devices for local neuromodulation of autonomic nerves
ES2532732T3 (es) Uso de un inhibidor de CDK para el tratamiento del glioma
US9271985B2 (en) Method of using vasoconstrictive agents during energy-based tissue therapy
Hsieh et al. Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts
CN103501789A (zh) 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
ES2273599B1 (es) Compuestos para el tratamiento de la fibrilacion auricular.
US20110190313A1 (en) Treatment of Pulmonary Arterial Hypertension
JP2002508315A (ja) 性的不能の治療に有効な組合せ
Schmeckpeper et al. RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease
JP2024012483A (ja) 頻脈の治療
Wang et al. Effects of sildenafil and/or muscle derived stem cells on myocardial infarction
AU2006230674A8 (en) Methods for the Treatment of Synucleinopathies
US7767686B2 (en) Method of using adenosine receptor blockers during tissue ablation
ES2222975T3 (es) Uso de antagonistas de pirimidina endotelina en animales de compañia.
US20120015968A1 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper-and sterile alpha motif-containing kinase (zak)
Mills Vasoconstriction and vasodilation in erectile physiology
US20250099455A1 (en) Treatment for congestive heart failure
WO2025155574A1 (en) Modulation of akap12 signalosome
Lawless et al. PDE5 inhibition improves symptom-free survival and restores transverse tubule loss and catecholamine responsiveness in heart failure
Martins et al. Angiotensin II effects on ischemic focal ventricular
Salloum et al. Phosphodiesterase-5 Inhibitors Improve Left Ventricular Function in Failing Hearts

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20070501

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2273599B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20251024